Bryan Hambley, MD, is a hematology oncologist, specializing in care for patients who have blood cancers of myeloma, lymphoma and leukemia.
Dr. Hambley is fellowship-trained in critical care medicine from Case Western Reserve University in Cleveland, Ohio, and in hematology from The Johns Hopkins Hospital in Baltimore, Maryland.
With particular expertise in rare hematologic disorders, Dr. Hambley specializes in the use of bone marrow transplantation and cellular therapies such as CAR T-cells for treatment. He chose these clinical focus areas because of the relationships he can form with patients during their care and enjoys bringing a team together to deliver the best possible results.
In 2019, Dr. Hambley completed a published study titled, Fibrinogen Consumption and Use of Heparin are Risk Factors for Delayed Bleeding During Acute Promyelocytic Leukemia Induction. The study focused on acute promyelocytic leukemia, a disease that can be deadly in the first weeks of treatment, but those who survive their initial hospitalization are nearly always cured of the disease.
Dr. Hambley is interested in optimizing treatment protocols and care delivery systems to patients with hematologic malignancies in the hospital, particularly those who are critically ill. He believes that improving the care that providers deliver after a life-changing cancer diagnosis is essential to advancing the clinical field and a patient's treatment.